These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33820494)

  • 1. Discovery of a rare
    Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion-Positive High-Grade Glioma.
    Simoneau J; Robertson P; Muraszko K; Maher CO; Garton H; Calvert R; Koschmann C; Upadhyaya SA; Mody R; Brown N; Kumar-Sinha C; Parmar H; Camelo-Piragua S; Franson AT
    J Natl Compr Canc Netw; 2024 Sep; 22(7):. PubMed ID: 39236755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
    Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
    Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
    Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
    Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilocytic astrocytoma with novel ATG16L1::NTRK2 fusion responsive to larotrectinib: a case report with genomic and functional analysis.
    Deland L; Keane S; Olsson Bontell T; Sjöberg Bexelius T; Gudinaviciene I; De La Cuesta E; De Luca F; Nilsson JA; Carén H; Mörse H; Abel F
    Oncologist; 2024 Sep; ():. PubMed ID: 39326005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jones KA; Bossler AD; Bellizzi AM; Snow AN
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
    Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
    J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
    Rudzinski ER; Hechtman J; Roy-Chowdhuri S; Rudolph M; Lockwood CM; Silvertown J; Wierzbinska J; Shen K; Norenberg R; Nogai H; Hong DS; Drilon A; Laetsch TW
    Cancer Genet; 2022 Jan; 260-261():46-52. PubMed ID: 34929613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an
    Mangum R; Reuther J; Bertrand KC; Chandramohan R; Kukreja MK; Paulino AC; Muzny D; Hu J; Gibbs RA; Curry DJ; Malbari F; Chintagumpala MM; Adesina AM; Fisher KE; Mack SC; Plon SE; Roy A; Parsons DW; Lin FY
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34651095
    [No Abstract]   [Full Text] [Related]  

  • 16. A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways.
    Pattwell SS; Arora S; Cimino PJ; Ozawa T; Szulzewsky F; Hoellerbauer P; Bonifert T; Hoffstrom BG; Boiani NE; Bolouri H; Correnti CE; Oldrini B; Silber JR; Squatrito M; Paddison PJ; Holland EC
    Nat Commun; 2020 Jun; 11(1):2977. PubMed ID: 32532995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
    Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine receptor kinase B is a drug target in astrocytomas.
    Ni J; Xie S; Ramkissoon SH; Luu V; Sun Y; Bandopadhayay P; Beroukhim R; Roberts TM; Stiles CD; Segal RA; Ligon KL; Hahn WC; Zhao JJ
    Neuro Oncol; 2017 Jan; 19(1):22-30. PubMed ID: 27402815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene.
    Gupta R; Dittmeier M; Wohlleben G; Nickl V; Bischler T; Luzak V; Wegat V; Doll D; Sodmann A; Bady E; Langlhofer G; Wachter B; Havlicek S; Gupta J; Horn E; Lüningschrör P; Villmann C; Polat B; Wischhusen J; Monoranu CM; Kuper J; Blum R
    Cancer Gene Ther; 2024 Sep; 31(9):1357-1379. PubMed ID: 39039193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.